Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Practice: Mini-Review

Free Access

Fibrotic Changes Mediating Acute Kidney Injury to Chronic Kidney Disease Transition

Ó hAinmhire E. · Humphreys B.D.

Author affiliations

Division of Nephrology, Washington University School of Medicine, St. Louis, MO, USA

Corresponding Author

Dr. Benjamin D. Humphreys

Division of Nephrology

Washington University School of Medicine

660 S. Euclid Ave., CB 8129, St. Louis, MO 63110 (USA)

E-Mail humphreysbd@wustl.edu

Related Articles for ""

Nephron 2017;137:264–267

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


End-stage renal disease (ESRD) is common, costly, and it results from progressive chronic kidney disease (CKD). ESRD claims many lives every year. It is increasingly recognized that episodes of acute kidney injury (AKI) predispose to the future development of CKD and ESRD. While our understanding of the pathophysiology of the AKI to CKD transition is improving, there are no validated therapeutic strategies to prevent this transition. In this review, we summarize the recent progress made in defining the cellular and molecular events underlying the AKI to CKD transition and highlight potential therapeutic targets and strategies to reduce the incidence of CKD following AKI.

© 2017 S. Karger AG, Basel


  1. Xu J, Murphy SL, Kochanek KD, Bastian BA: Deaths: final data for 2013. Natl Vital Stat Rep 2016;64:1-119.
  2. Ferenbach DA, Bonventre JV: Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol 2015;11:264-276.
  3. Chang-Panesso M, Humphreys BD: Cellular plasticity in kidney injury and repair. Nat Rev Nephrol 2017;13:39-46.
  4. Kusaba T, Lalli M, Kramann R, Kobayashi A, Humphreys BD: Differentiated kidney epithelial cells repair injured proximal tubule. Proc Natl Acad Sci U S A 2014;111:1527-1532.
  5. Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV: Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008;118:1657-1668.
  6. Grande MT, Sanchez-Laorden B, Lopez-Blau C, De Frutos CA, Boutet A, Arevalo M, et al: Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med 2015;21:989-997.
  7. Kumar S, Liu J, Pang P, Krautzberger AM, Reginensi A, Akiyama H, et al: Sox9 activation highlights a cellular pathway of renal repair in the acutely injured mammalian kidney. Cell Rep 2015;12:1325-1338.
  8. Kang HM, Huang S, Reidy K, Han SH, Chinga F, Susztak K: Sox9-positive progenitor cells play a key role in renal tubule epithelial regeneration in mice. Cell Rep 2016;14:861-871.
  9. Ismail OZ, Zhang X, Wei J, Haig A, Denker BM, Suri RS, et al: Kidney injury molecule-1 protects against Gα12 activation and tissue damage in renal ischemia-reperfusion injury. Am J Pathol 2015;185:1207-1215.
  10. Humphreys BD, Xu F, Sabbisetti V, Grgic I, Movahedi Naini S, Wang N, et al: Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013;123:4023-4035.
  11. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV: Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16:535-543, 1p following 143.
  12. Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK: Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol 2015;26:1765-1776.
  13. Fabian SL, Penchev RR, St-Jacques B, Rao AN, Sipilä P, West KA, et al: Hedgehog-Gli pathway activation during kidney fibrosis. Am J Pathol 2012;180:1441-1453.
  14. Zhou D, Tan RJ, Liu Y: Sonic hedgehog signaling in kidney fibrosis: a master communicator. Sci China Life Sci 2016;59:920-929.
  15. Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, et al: Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 2015;16:51-66.
  16. Kramann R, Fleig SV, Schneider RK, Fabian SL, DiRocco DP, Maarouf O, et al: Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. J Clin Invest 2015;125:2935-2951.
  17. Maarouf OH, Ikeda Y, Humphreys BD: Wnt signaling in kidney tubulointerstitium during disease. Histol Histopathol 2015;30:163-171.
  18. Zhou D, Tan RJ, Fu H, Liu Y: Wnt/β-catenin signaling in kidney injury and repair: a double-edged sword. Lab Invest 2016;96:156-167.
  19. DiRocco DP, Kobayashi A, Taketo MM, McMahon AP, Humphreys BD: Wnt4/β-catenin signaling in medullary kidney myofibroblasts. J Am Soc Nephrol 2013;24:1399-1412.
  20. Maarouf OH, Aravamudhan A, Rangarajan D, Kusaba T, Zhang V, Welborn J, et al: Paracrine Wnt1 drives interstitial fibrosis without inflammation by tubulointerstitial cross-talk. J Am Soc Nephrol 2016;27:781-790.
  21. Zhou L, Li Y, Zhou D, Tan RJ, Liu Y: Loss of Klotho contributes to kidney injury by derepression of Wnt/β-catenin signaling. J Am Soc Nephrol 2013;24:771-785.
  22. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y: Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009;20:765-776.
  23. Surendran K, Schiavi S, Hruska KA: Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 2005;16:2373-2384.
  24. Zhou D, Li Y, Lin L, Zhou L, Igarashi P, Liu Y: Tubule-specific ablation of endogenous β-catenin aggravates acute kidney injury in mice. Kidney Int 2012;82:537-547.
  25. Andersson ER, Sandberg R, Lendahl U: Notch signaling: simplicity in design, versatility in function. Development 2011;138:3593-3612.
  26. Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, et al: Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett 2015;369:20-27.
  27. Sharma S, Sirin Y, Susztak K: The story of Notch and chronic kidney disease. Curr Opin Nephrol Hypertens 2011;20:56-61.
  28. Kobayashi T, Terada Y, Kuwana H, Tanaka H, Okado T, Kuwahara M, et al: Expression and function of the Delta-1/Notch-2/Hes-1 pathway during experimental acute kidney injury. Kidney Int 2008;73:1240-1250.
  29. Walsh DW, Roxburgh SA, McGettigan P, Berthier CC, Higgins DG, Kretzler M, et al: Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim Biophys Acta 2008;1782:10-21.
  30. Murea M, Park JK, Sharma S, Kato H, Gruenwald A, Niranjan T, et al: Expression of notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int 2010;78:514-522.
  31. Djudjaj S, Chatziantoniou C, Raffetseder U, Guerrot D, Dussaule JC, Boor P, et al: Notch-3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury. J Pathol 2012;228:286-299.
  32. Bielesz B, Sirin Y, Si H, Niranjan T, Gruenwald A, Ahn S, et al: Epithelial notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010;120:4040-4054.

Article / Publication Details

First-Page Preview
Abstract of Clinical Practice: Mini-Review

Received: March 01, 2017
Accepted: April 02, 2017
Published online: June 09, 2017
Issue release date: December 2017

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.